Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.

BMC Cancer · 2022 · PMC9446552 · PMID 36064386

Europe PMC DOI

hedged sentence

0.2800

closest p · 5.6× alpha

0.2800

boldest claim

The sentences

did not reach statistical significancep = 0.28not close (p > 0.1)

Among these 10 patients, the ORR for second-line sintilimab plus docetaxel was 50% (5/10) and was numerically higher than those who did not receive bevacizumab (30%, 6/20); however, the difference did not reach statistical significance ( p = 0.28).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.